October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Oriol Mirallas: PEACE-3 – Enzalutamide + Radium-223 vs Enzalutamide alone
Sep 17, 2024, 15:12

Oriol Mirallas: PEACE-3 – Enzalutamide + Radium-223 vs Enzalutamide alone

Oriol Mirallas shared a post on X:

Presidential Session at ESMO.

PEACE-3: Enzalutamide (Enza) + Radium-223 (Ra223) vs Enzalutamide alone. Presented by Silke Gillessen.

  • Median progression-free survival (mPFS): 19.4 months vs 16.4 months, HR 0.69.
  • Time to treatment (TTT) HR: 0.57.

Grade 3 toxicity: 28% in combination therapy vs 19% with Enzalutamide alone.

Discussed by Karim Fizazi.

Oriol Mirallas

Source: Oriol Mirallas/X

Oriol Mirallas is a Medical Oncologist at the Phase I Unit at Vall Hebron Institute of Oncology (VHIO) with a focus on translational and clinical cancer research. He is currently pursuing a PhD on resistance mechanisms to new drugs, using liquid biopsy analysis.

Silke Gillessen is the Medical and Scientific Director of the Oncology Institute of Southern Switzerland and a Full Professor at University of Italian Switzerland. Her expertise focuses on genitourinary (GU) cancers.